News

Make sure you meet with us and discuss your projects and demands as well as new developments and service opportunities in person!

Please contact Luca Covello to arrange a meeting prior to the show.

Forthcoming Events

  • CPhI North America, May 16-18, 2017 Pennsylvania Convention Center Philadelphia, PA, USA (BOOTH 2253)
  • CF@BO 2017, June 4-6, 2017 Bologna, Italy
  • CPhI Worldwide, 24 - 26 October 2017 Messe Frankfurt, Germany  (STAND No: 40B40)

order by visits date title

Sostanze Altamente Attive: Rischi E Contenimento

Polycrystalline e CSV Life Sciences organizzano la Giornata di Studio sul tema "SOSTANZE ALTAMENTE ATTIVE: RISCHI E CONTENIMENTO" che si terrà a Bologna il giorno 16 Novembre 2017.   Sedi delle giornate di studio BOLOGNA 1ª edizione 16 Novembre 2017 - Polycrystalline Via della Cooperazione 29 - 40059 Medicina   Quota di partecipazione PARTECIPAZIONE GRATUITA FINO AD ESAURIMENTO POSTI   Per info ed iscrizioni luca.covello@polycrystalline.it  - 3938498462 Programma

Read all

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project”, because at Polycrystalline we offer a transparent and streamlined partnership, with joint responsibilities and interactions. In our unique interface there are four major features that summarize our governance: E

Read all

Controlled Substances Studies & Analysis

PolyCrystalLine received the authorization N°487/2016 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project”, because at Polycrystalline we offer a transparent and streamlined partnership, with joint responsibilities and interactions. In our unique interface there are four major features that summarize our governance: E

Read all

Highly Potent API

Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment of major depres

Read all

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GE

Read all

Pagina 1 di 2
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb